NYT: “Invisible Residents” Studies of the Human Microbiome
For a century, doctors have waged war against bacteria, using antibiotics as their weapons. But that relationship is changing as scientists become more familiar with the 100 trillion microbes that call us home — collectively known as the microbiome. “I would like to lose the language of warfare,” said Julie Segre, a senior investigator at the [...]
NCATS Adds to “Discovering New Therapeutic Uses for Existing Molecules” Pilot Program
Link to NIH’s Press Release Discovering New Therapeutic Uses for Existing Molecules is a collaborative pilot program designed to develop partnerships between pharmaceutical companies and the biomedical research community to advance therapeutic development. This innovative program matches researchers with a selection of molecular compounds from industry to test ideas for new therapeutic uses, with the [...]
Braingate: Turning Thoughts into Actions
A new study in Nature reports that two people with tetraplegia were able to reach for and grasp objects in three-dimensional space using robotic arms that they controlled directly with brain activity. They used the BrainGate neural interface system, an investigational device currently being studied under an Investigational Device Exemption. One participant used the system to serve herself coffee for the first time since becoming paralyzed nearly 15 years ago.
AIMBE Holds First 2012 Congressional Briefing on Translational Research
WASHINGTON, D.C.—The American Institute for Medical and Biological Engineering (AIMBE) held its first 2012 Congressional Briefing this past Monday, April 9, 2012 entitled How Translational Research is Transforming Patient Care and the American Economy. The briefing, held on Capitol Hill in the Rayburn building, drew congressional staffers, representatives from AIMBE’s Council of Societies, and other interested individuals.
AIMBE Past-President Thomas Skalak Provides Congressional Testimony on FY 2013 Budget Request
WASHINGTON, D.C.—Thomas C. Skalak, past-president of the American Institute for Medical and Biological Engineering (AIMBE) and Vice President for Research at the University of Virginia, provided oral and written testimony to the U.S. House Subcommittee on Commerce, Justice, Science, and Related Agencies under the U.S. House Committee on Appropriations concerning the FY 2013 Budget Request and how its priorities set the stage for vital funding of research leading to American innovation.
What is Biomedical Engineering?
AIMBE Class of 2012 College of Fellows Inducted in Washington, DC
Washington, DC— The American Institute for Medical and Biological Engineering (AIMBE) has inducted 94 new AIMBE Fellows to the 2012 class of the College of Fellows. The long process for new AIMBE Fellows began with nominations by their peers early last year. Each nominee was also screened by committees of Fellows within their bioengineering specialty. Finally, a final election by the entire College of Fellows was completed in late 2011.
Top Inventors and Entrepreneurs Come to Washington
WASHINGTON, D.C. — America’s leading medical and biological engineers will gather in Washington, DC for the American Institute for Medical and Biological Engineering’s (AIMBE) 2012 Annual Event—an opportunity to discuss the latest advancements in the field and to join forces in support of public policies that assure a continuous flow of medical and biological engineering innovation for the benefit of humanity.
AIMBE Recognizes President Obama’s FY 2013 Budget
WASHINGTON, DC — The American Institute for Medical and Biological Engineering (AIMBE) recognizes President Obama’s FY 2013 budget and how its priorities affect the bioengineering community.
Amendments Plague Renewal of Bill to Approve FDA Authority
By Rebecca Adams, CQ Healthbeat Associate Editor Congress must renew a law to allow the Food and Drug Administration to continue approving life-saving drugs and devices. But this renewal has already attracted a myriad of amendments unrelated to the user fees that lawmakers are being asked to approve. The FDA relies on user fees from [...]
